vsa003
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Jun 30, 2023 (NCT05851066)
Timeline
Indications
Mechanism of action
- Angiopoietin-related protein 3MODULATOR
ANGPTL3 modulator
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06712771 | Phase 3 | Dec 2, 2024 | Visirna Therapeutics HK Limited |
| NCT05851066 | Phase 1 | Jun 30, 2023 | Visirna Therapeutics HK Limited |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Visirna Therapeutics HK Limited | For profit | 2 | 2 | 2 | 2023 |
1 organizations
Page 1 / 1